16 September 2026 editorial review · Trial
CNP-103: tolerogenic nanoparticles in recent-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Removed retired roadmap links; checked registry/endpoints or accessible primary abstract. Full results/safety tables were not accessible; no new efficacy inferred.
Registry: NCT06783309. Registered endpoint checked: Safety (Day 1 Through Day 365); Immune Safety (Day 1 Through Day 365). Eligibility check: Registry age 12 Years to 35 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.